Trial NCT04790786
Publication OPTIMISE-C19 - Huang D, JAMA Netw Open (2022) (published paper)

Funding: Mixed (The Federal COVID Response Team (formerly called Operation Warp Speed) supplies mABs to UPMC, participates in design discussions, and is provided regular updates. UPMC supports this trial with resources and internal funds, and leadership was involved in all aspects of the trial including design, analysis, data interpretation, and manuscript preparation. The US government provided casirivimab-imdevimab, and GlaxoSmithKline and Vir Biotechnology provided sotrovimab. Preliminary results were shared with GlaxoSmithKline and Vir Biotechnology before preprint submission, but the organization had no role in manuscript preparation or interpretation of results.)
Conflict of interest: No